title: Myelodysplastic syndrome/acute myelogenous leukaemia related to adjuvant chemotherapy with oral pyrimidine anti-metabolites.
authors: M
authors: M
authors: Abe
authors: Y
authors: Y
authors: Tanaka
authors: M
authors: M
authors: Shinohara
authors: M
authors: M
authors: Kosaka
authors: T
authors: T
authors: Matsumoto
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects; D004334:Drug Administration Schedule; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced*; D008297:Male; D009190:Myelodysplastic Syndromes / Q000139:chemically induced*; D009378:Neoplasms, Multiple Primary / Q000188:drug therapy; D005641:Tegafur / Q000009:adverse effects*; D013997:Time Factors; D014498:Uracil / Q000009:adverse effects
chemical_list: D000964:Antimetabolites, Antineoplastic; D018906:Antineoplastic Agents, Alkylating; D005641:Tegafur; D014498:Uracil